Dr. Gaylis is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
2801 NE 213th St
Ste 801
Aventura, FL 33180Phone+1 305-652-6676Fax+1 305-932-6335
Summary
- Dr. Norman Gaylis is a rheumatologist in Aventura, FL and is affiliated with Aventura Hospital and Medical Center. He received his medical degree from University of the Witwatersrand and has been in practice 44 years. He is experienced in systemic lupus erythematosus, osteoarthritis, rheumatoid arthritis, and gout.
Education & Training
- University of Miami/Jackson Health SystemFellowship, Rheumatology, 1979 - 1981
- Mount Sinai Medical Center of FloridaResidency, Internal Medicine, 1976 - 1979
- University of the WitwatersrandClass of 1973
Certifications & Licensure
- FL State Medical License 1977 - 2025
- GA State Medical License Active through 1979
- American Board of Internal Medicine Internal Medicine
- American Board of Internal Medicine Rheumatology
Awards, Honors, & Recognition
- Top Doctors:South Florida Castle Connolly, 2012
- Top Doctors: Florida Castle Connolly, 2000
- Fellow (FACR) American College of Rheumatology
Clinical Trials
- Impact of Rituximab on MRI Evidence of Disease Activity in Patients With Moderate to Severe Rheumatoid Arthritis Start of enrollment: 2007 Feb 01
- A Study to Evaluate the Efficacy and Safety of CEP-33457 in Participants With Systemic Lupus Erythematosus (SLE) Start of enrollment: 2010 Jun 24
- The Effect of Certolizumab Pegol on MRI Synovitis and Bone Edema in Rheumatoid Arthritis Patients Start of enrollment: 2010 Sep 01
- Join now to see all
Publications & Presentations
PubMed
- Understanding immune dysregulation in post-acute sequelae of COVID-19 (PASC)-The hunt for effective treatments.Norman B Gaylis, Otto O Yang
The Journal of Infection. 2024-05-01 - 'Totality of Evidence' Approach in the Development of GP2017, an Approved Adalimumab Biosimilar.Norman Gaylis, Charlotte Both, Lena Lemke, Oliver von Richter, Paul Yamauchi
Advances in Therapy. 2024-05-01 - A plain language summary describing how two different concentrations of GP2017, a biosimilar adalimumab medicine, are associated with similar drug levels within the body.Silvio Danese, Piotr Wiland, Russell Cohen, Norman Gaylis, Charlotte Both
Immunotherapy. 2023-12-01
Press Mentions
- COVID-19 Nasal Spray Shows Strong Immune Response in StudyApril 7th, 2023
- COVID Vaccine Nasal Spray Shows Strong Immune Response in Study: ‘Could Be a Game Changer’April 6th, 2023
- 5 Questions to Ask Your Doctor for a COVID-19 Treatment Strategy (Before Infection)April 3rd, 2023
- Join now to see all
Professional Memberships
- Fellow
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence: